ライフサイエンスコーパス: LNP

1 LNP cells were also associated with changes to signaling

2 LNP composition is based upon clinically relevant formul

3 LNP is a genetic trait, but is typically determined by L

4 LNP is also required for infection by the mycorrhizal fu

5 LNP is present on the surface of the root hairs, and tre

6 LNP-delivered mRNA can be used to treat monogenic retina

7 LNP-dsP21-322-2'F treatment also facilitates p21 activat

8 LNPs containing OA is a promising nanocarrier system for

9 LNPs that contained ionizable lipids with low pKa and un

10 LNPs treated with mouse serum showed higher levels of si

11 LNPs were incubated with 50% serum from different specie

12 d as markedly lactose intolerant (S-LNP), 13 LNP subjects who denied lactose intolerance (A-LNP), and

13 A library of 13 LNPs encapsulating RAS protease was designed, and each f

14 gnificantly from 2.5 (95% CI 1.8-3.3) at 15% LNP to 1.3 (1.2-1.9; p=0.014) at 40% LNP.

15 Inventory 2 (MMPI-2) was administered to 19 LNP subjects self-described as markedly lactose intolera

16 at 15% LNP to 1.3 (1.2-1.9; p=0.014) at 40% LNP.

17 P subjects who denied lactose intolerance (A-LNP), and 10 lactase-persistent individuals who believed

18 ntly greater gaseous symptoms than did the A-LNP subjects during both treatment periods.

19 Additionally, AA15V LNP-sSE-SCTs enable SE-SCT expression in ex vivo human g

20 Additionally, LNP-DNA vaccination in young pigs provides a valuable mo

21 Additionally, LNP-M effectively delivered DNA-encoded antigens, such a

22 Additionally, LNPs encapsulating Cas9 mRNA with sgAi9 enabled in vivo

23 Mice were administered LNPs encapsulating human codon-optimized ARG1 mRNA every

24 onally, we show that delivery of aerosolized LNP-DNAI1 mRNA to NHPs leads to detectable levels of new

25 ructure of the barcoded nucleic acid affects LNP in vivo delivery.

26 amine 2000, a commercial transfection agent, LNPs containing OA delivered microRNA-122 in a more effi

27 orm of the non-parametric nonlinearity in an LNP model.

28 More generally, this suggests an LNP which delivers mRNA to one inflammatory disease may

29 o 28 cell types in vivo, it is found that an LNP formulated with oxidized cholesterol and no targetin

30 b self-amplifying RNA encapsulated within an LNP substantially increased immunogenicity compared with

31 ell as the cluster-associated genes Evx2 and LNP, in the paddlefish Polyodon spathula, a basal ray-fi

32 minated between lactase persistence (LP) and LNP following lactose challenge with an area under the r

33 Both 2'-fluoro modification and LNP formulation also improve duplex stability in urine.

34 provided in vitro evidence that Arabidopsis LNPs have E3 ubiquitin ligase activity and that LNP1 can

35 l features of composite formulations such as LNPs to predict their performance in an end-to-end manne

36 Cocoa butter LNPs presented an equally complete digestion as corn oil

37 because of the high rate of dissimulation by LNP subjects.

38 ER fusion is completed, RHD3 is degraded by LNPs so that nascent three-way junctions can be stabiliz

39 Whilst all cationic LNP (cLNP) formulations promoted high association with c

40 ining family O member 1 (Plekho1) siRNA (CH6-LNPs-siRNA).

41 1:3 IL-coated LNPs demonstrated the most pronounced improvement in RBC

42 multiple cell lines and genomic loci, CRISPR LNP-SNAs induce insertion-deletion mutations at average

43 RNA targeting catenin beta 1 (CTNNB1; CTNNB1-LNP), scrambled sequence (Scr-LNP), or phosphate-buffere

44 se in tumor burden was evident in the CTNNB1-LNP group versus all controls, which was associated with

45 Db-LNP is also present in the root pericycle where its leve

46 Db-LNP is present on the surface of young and emerging root

47 Maximum levels of Db-LNP are found in 2-d-old roots, and the expression of th

48 ain a lectin/nucleotide phosphohydrolase (Db-LNP) that binds to the Nod factor signals produced by rh

49 In this study we show that Db-LNP is differentially distributed along the surface of t

50 hese results support the possibility that Db-LNP is involved in the initiation of the Rhizobium legum

51 Over the past three decades, LNP proportion has increased, mainly reflecting enhanced

52 t of technology to produce precisely defined LNP formulations, with throughput that can scale from di

53 drugs that are highly pure and well-defined, LNP drug products can exhibit heterogeneity in size, com

54 specifically designed for hepatic delivery, LNPs containing OA showed comparable liver accumulation

55 In the context of liver and spleen delivery, LNPs that exhibited high b-mRNA delivery also yielded hi

56 al protein production in the spleen, despite LNPs being observed transiently in the liver and other o

57 2) was greater than plasma glucose to detect LNP following lactose challenge whereas values obtained

58 o evaluate the diagnostic accuracy to detect LNP using these commonly measured LM markers after both

59 Herein, we tested eleven different LNP variants for their ability to deliver mRNA to the ba

60 FIND to quantify how 75 chemically distinct LNPs delivered mRNA to 28 cell types in vivo, it is foun

61 70 MDa, 31 MDa higher than that of the empty LNP sample.

62 signed and evaluated a library of engineered LNPs containing barcoded mRNA (b-mRNA) to accelerate the

63 ich altered the ECM composition and enhanced LNP and mRNA penetration into cellular spheroids.

64 treatment with LNP-formulated dsP21-322-2'F (LNP-dsP21-322-2'F) or one of its nonformulated variants.

65 cularly for those whose tumors contained few LNP cells.

66 he discovery of next-generation reagents for LNP-mediated nucleic acid delivery.

67 sm, was used as the diagnostic reference for LNP.

68 , greater than 50% mFXN protein derived from LNPs was detected seven days after intravenous administr

69 lated that the amount of siRNA released from LNPs after going through these treatments can be used as

70 The amount of siRNA released from LNPs was determined using spectrophotometry employing th

71 t osteoblast-specific aptamer-functionalized LNPs could act as a new RNAi-based bone anabolic strateg

72 Furthermore, LNP-Tmprss6 siRNA treatment of Hbb(th3/+) mice substanti

73 liver homogenates demonstrated efficient FXN LNP uptake in hepatocytes and revealed that the mitochon

74 days after intravenous administration of FXN LNPs, suggesting that the half-life of mFXN in vivo exce

75 Moreover, when FXN LNPs were delivered by intrathecal administration, we de

76 g identified 14 out of 40 subjects as having LNP (C/C(13910) and G/G(22018)).

77 ing T cells was observed in tumors with high LNP cell counts.

78 A deeper understanding of how LNP cargo, lipid composition, stoichiometry, size, struc

79 The discrepant effects of TLR4 on i) LNP uptake and ii) translation suggests TLR4 activation

80 Importantly, LNPs were also able to boost DEN-80E specific CD4+ and C

81 developed biodegradable lipids which improve LNPs clearance and reduce toxicity.

82 w and meta-regression to quantify changes in LNP over time and the impact of this change on survival

83 o successfully develop and ensure quality in LNP pharmaceuticals.

84 signaling responses could be reactivated in LNP cells, indicating that BCR signaling is not missing

85 not explain the absence of BCR signaling in LNP tumor cells, and other signaling responses were inta

86 c acid [poly(I:C)], was also encapsulated in LNPs to further elicit BCMA-specific immune response.

87 11 studies with prognostic data, increasing LNP was associated with improved overall survival in bot

88 tosis and endocytosis as an ApoE-independent LNP cellular uptake pathway in the liver.

89 Interestingly, LNPs with identical formulation parameters that encapsul

90 ncorporation of C-24 alkyl phytosterols into LNPs (eLNPs) enhances gene transfection and the length o

91 g inflammation markers following intravenous LNP administration.

92 ies and were compared to benchmark ionizable LNPs (iLNPs).

93 by RHD3 to newly formed three-way junctions, LNPs act negatively with RHD3 to stabilize the nascent t

94 The high targeting efficiency of alphaPD-L1-LNP to human TAMCs from GBM patients further validated t

95 We demonstrated that this system (alphaPD-L1-LNP) enabled effective and specific delivery of therapeu

96 icating that this platform can identify lead LNP candidates as well as optimal formulation parameters

97 an FIX (hFIX) mRNA encapsulated in our LUNAR LNPs results in a rapid pulse of FIX protein (within 4-6

98 We introduce a new method (LNP) that reports reasonable p-values and also detects m

99 Additionally, CD47-modified LNPs showed diminished inflammatory effects on hepatic t

100 Kupffer cells at clinical doses; unlike most LNPs, this LNP does not preferentially target hepatocyte

101 A single dose of combined 5xM2e mRNA LNP and split vaccines resulted in significantly enhance

102 AMG1541 mRNA LNPs substantially reduced expression in the liver follo

103 Using a mini-library of b-mRNA LNPs formulated via microfluidic mixing, we show that th

104 Administration of Cre-mRNA LNPs to Ai9 mice resulted in robust tdTomato expression

105 Two doses of modified mRNA LNPs encoding prM-E genes that produced virus-like parti

106 erved in the full-length gB protein and mRNA-LNP groups, though not in ectodomain-vaccinated rabbits.

107 Furthermore, the gB mRNA-LNP vaccine enhanced the breadth of IgG binding response

108 ta demonstrate that nucleoside-modified mRNA-LNP elicits rapid and durable protective immunity and th

109 single immunization with 10 ug modified mRNA-LNP protected most susceptible mice from mousepox, and b

110 gs suggest that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses

111 that the use of gB nucleoside-modified mRNA-LNP vaccines is a viable strategy for improving on the p

112 gB nucleoside-modified mRNA-LNP-immunized rabbits exhibited an enhanced durability o

113 -encapsulated nucleoside-modified mRNA (mRNA-LNP) encoding the pre-membrane and envelope glycoprotein

114 encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding the full-length SARS-CoV-2 spike

115 s the packaging distribution to fit the mRNA-LNP data.

116 with 30 mug of nucleoside-modified ZIKV mRNA-LNP protected mice against ZIKV challenges at 2 weeks or

117 Here, we generated mRNA-LNPs by incorporating HPLC purified, 1-methylpseudouridi

118 injected with 0.005-0.250mg/kg doses of mRNA-LNPs by 6 different routes and high levels of protein tr

119 ttleneck in the field is the release of mRNA-LNPs from the endosomal pathways into the cytosol of cel

120 acheal deliveries led to trafficking of mRNA-LNPs systemically resulting in active translation of the

121 RNA staining after prolonged shaking of mRNA-LNPs.

122 A single dose of TALEN mRNA-LNPs reduced plasma Lp(a) levels in mice by over 80%, wh

123 Additionally, mRNA/LNP-induced pyroptosis sensitizes tumors to anti-PD-1 im

124 LF1-specific transcriptional activator (mTZ3-LNP) is synthesized for EBV-targeted therapy.

125 in encapsulated within a lipid nanoparticle (LNP) as a vaccine.

126 The development of lipid nanoparticle (LNP) based small interfering RNA (siRNA) therapeutics pr

127 tionic helper lipid to a lipid nanoparticle (LNP) can increase lung delivery and decrease liver deliv

128 therapeutic efficacy of lipid nanoparticle (LNP) delivery of a single nucleoprotein-targeting (NP-ta

129 We engineered a lipid nanoparticle (LNP) encapsulated modified mRNA vaccine encoding wild-ty

130 we rationally designed a lipid nanoparticle (LNP) formulation surface-functionalized with an anti-PD-

131 ological evaluation of a lipid nanoparticle (LNP) system that can encapsulate mRNA, navigate to the s

132 P35 gene encapsulated in lipid nanoparticle (LNP) technology with increased potency beyond formulatio

133 th squalene adjuvant, or lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA encoding full

134 n primates injected with lipid nanoparticle (LNP)-formulated Andes virus or Zika virus DNA vaccines a

135 were formulated in a lipidoid nanoparticle (LNP).

136 ve (dsP21-322-2'F) into lipid nanoparticles (LNP) for intravesical delivery.

137 atenin mice with EnCore lipid nanoparticles (LNP) loaded with a Dicer substrate small interfering RNA

138 Here, we designed lipid-based nanoparticles (LNPs) coated with anti-CD38 monoclonal antibodies that a

139 een developed for lipid-based nanoparticles (LNPs) for delivery of siRNA and microRNA (miRNA).

140 Lipid-based nanoparticles (LNPs) remain at the forefront of potent delivery vectors

141 sequestration of lipid-based nanoparticles (LNPs) remains a formidable barrier to delivery.

142 Lipid-like nanoparticles (LNPs) have potential as non-viral delivery systems for m

143 Lipid nanoparticles (LNPs) are efficient carriers for short-interfering RNAs

144 alcohol (AAA) ionizable lipid nanoparticles (LNPs) capable of delivering human mRNA with unprecedente

145 to measure how over 100 lipid nanoparticles (LNPs) deliver mRNA that functions in the cytoplasm of ta

146 aptamer-functionalized lipid nanoparticles (LNPs) encapsulating osteogenic pleckstrin homology domai

147 uality siRNA-containing lipid nanoparticles (LNPs) for a large number of materials, we have shown tha

148 r in vivo evaluation of lipid nanoparticles (LNPs) for systemic small interfering RNA (siRNA) deliver

149 Libraries of ionizable lipid nanoparticles (LNPs) have been designed to encapsulate mRNA, prevent it

150 gradable liver-targeted lipid nanoparticles (LNPs) have potentially enabled a new generation of safer

151 mple, mRNA delivered by lipid nanoparticles (LNPs) is being considered to treat inflammation, but whe

152 ss6 siRNA formulated in lipid nanoparticles (LNPs) that are preferentially taken up by the liver woul

153 h for the evaluation of lipid nanoparticles (LNPs) to identify relationships between structure, biolo

154 ulated in biodegradable lipid nanoparticles (LNPs) to produce functional PCC enzyme in liver.

155 l mRNA delivery through lipid nanoparticles (LNPs) to treat a Factor IX (FIX)-deficient mouse model o

156 NA (siRNA) delivered in lipid nanoparticles (LNPs) using cellular trafficking probes in combination w

157 study the formation of lipid nanoparticles (LNPs) with low (corn and olive oil) or high temperature

158 that can be similar to lipid nanoparticles (LNPs), it is hypothesized that LNPs devoid of targeting

159 eve efficient delivery, lipid nanoparticles (LNPs), particularly those based on ionizable amino-lipid

160 XN mRNA, in the form of lipid nanoparticles (LNPs), was administered intravenously in adult mice.

161 ering RNA (siRNA) using lipid nanoparticles (LNPs), we developed a self-amplifying RNA vaccine.

162 with ionizable cationic lipid nanoparticles (LNPs).

163 The results showed that neither LNP group had a significant increase in symptoms (P < 0.

164 egligible symptoms in lactase-nonpersistent (LNP) individuals self-described as being severely lactos

165 vo DNA barcoding is used to discover a novel LNP that delivers mRNA to Kupffer cells at clinical dose

166 der cancer by intravesical administration of LNP-formulated RNA duplexes.

167 that permits the high-resolution analysis of LNP size distribution in its native solution condition.

168 Intravesical delivery of LNP-dsP21-322-2'F into mouse bladder results in urotheli

169 of LNP pKa as one of the key determinants of LNP function and activity both in vitro and in vivo.

170 This study showed accurate diagnosis of LNP by breath H(2) irrespective of the substrate used, a

171 ple parameters enabled the identification of LNP pKa as one of the key determinants of LNP function a

172 Here, we show that antisense inhibition of LNP blocks nodulation in Lotus japonicus.

173 regulator of the major recycling pathways of LNP-delivered siRNAs.

174 ch significantly improved the performance of LNP-mRNA complexes in vitro and in vivo.

175 In 20 studies, across a range of LNP proportions from 15% to 40%, the hazard ratios for o

176 A better understanding of LNP-mediated SAM uptake and release mechanisms in differ

177 D3 is degraded more slowly in the absence of LNPs as well as in the presence of MG132 and concanamyci

178 However, repeated administrations of LNPs may lead to accumulation of delivery materials and

179 ful prescreening tool for the advancement of LNPs in vivo.

180 celerate the in vivo screening and design of LNPs for mRNA therapeutic applications such as CRISPR-Ca

181 We believe that the rational design of LNPs with multiple amine-lipids increases the material s

182 rk can help to facilitate the development of LNPs as a well-defined pharmaceutical product.

183 siRNA undergoes exocytosis through egress of LNPs from late endosomes/lysosomes.

184 s are required for initial cellular entry of LNPs through macropinocytosis, including proton pumps, m

185 rategy is to mimic the in vivo experience of LNPs after systemic administration, such as interactions

186 scientific knowledge in the heterogeneity of LNPs as well as high-resolution techniques that permit t

187 molecular weight, and siRNA cargo loading of LNPs could be achieved.

188 NP design may facilitate the optimization of LNPs for other administration routes and therapeutics.

189 ever, little is known about the potential of LNPs to deliver mRNA.

190 This work evidences the potential of LNPs to protect lipophilic bioactive compounds with a hi

191 However, in the presence of LNPs, the degradation of RHD3 is promoted.

192 can be broadly applied to a diverse range of LNPs.

193 nt cells show enhanced cellular retention of LNPs inside late endosomes and lysosomes, and increased

194 e of cholesterol in subcellular transport of LNPs carrying mRNA and emphasize the need for greater in

195 ed an equally complete digestion as corn oil LNPs and a high beta-carotene bioaccessibility, which wa

196 rovides similar size distribution results on LNPs compared to FFF.

197 icle assembly process, it was found that one LNP (A) possessed a narrow size and molecular weight dis

198 assay was developed to screen and rank order LNPs for in vivo evaluation.

199 tion suggests TLR4 activation can "override" LNP targeting, even after mRNA is delivered into target

200 A similarly prepared mRNA-packaged LNP sample has a peak mass at ~70 MDa, 31 MDa higher tha

201 Acid-degradable PEG-LNPs achieved notably superior transfection in the heart

202 A subset of four top-performing LNP formulations was identified and further evaluated fo

203 Adult lactase non-persistence (LNP) is due to low lactase expression, resulting in lact

204 entified LECTIN NUCLEOTIDE PHOSPHOHYDROLASE (LNP) as a Nod factor-binding protein.

205 This lectin-nucleotide phosphohydrolase (LNP) has a substrate specificity characteristic of the a

206 s to delivery such as siRNA entrapment, pKa, LNP stability, and cell uptake as a collective may serve

207 he parameters of a linear-nonlinear-Poisson (LNP) model, and that the empirical single-spike informat

208 We thus (i) detail a Log-normal-Poisson (LNP) background model that accounts for this variability

209 a of the anus (SCCA), lymph node positivity (LNP) indicates poor prognosis for survival and is centra

210 ct measurement of intra-lymph node pressure (LNP) demonstrated a decrease in expanding PLN versus WT

211 These lymphoma negative prognostic (LNP) cells increased as tumors relapsed following chemot

212 azido-acetal linker and used to generate RD-LNPs, which significantly improved the performance of LN

213 ll-like receptor 4 (TLR4) activation reduced LNP-mediated mRNA delivery.

214 n in all tested cell types, without reducing LNP uptake; inhibiting TLR4 or its downstream effector p

215 radiotherapy as the main treatment, reported LNP proportions (all studies), and reported overall surv

216 .5 mg kg(-1) and, unlike previously reported LNPs, do not preferentially target hepatocytes.

217 We identified 62 studies reporting LNP proportions, which included 10 569 patients.

218 Two representative LNPs with similar bulk properties were evaluated in-dept

219 nding of this process will enable better RNA-LNP designs with improved efficiency to unlock new thera

220 S-LNP subjects have underlying flatulence that is misattri

221 high score on the "lie" validity scale for S-LNP subjects.

222 However, S-LNP subjects reported significantly greater gaseous symp

223 -described as markedly lactose intolerant (S-LNP), 13 LNP subjects who denied lactose intolerance (A-

224 saRNA LNP immunizations induce a Th1-biased response in mice,

225 Additionally, lyophilized saRNA-LNPs were efficiently delivered into the skin via microf

226 CTNNB1; CTNNB1-LNP), scrambled sequence (Scr-LNP), or phosphate-buffered saline for multiple cycles.

227 (CF), NG-ABE8e messenger RNA (mRNA)-sgR553X LNPs mediated >95% cystic fibrosis transmembrane conduct

228 eated animals succumbed to disease, NP siRNA-LNP treatment conferred 100% survival of RAVV-infected m

229 with MARV or RAVV and treated with NP siRNA-LNP, with MARV-infected animals beginning treatment four

230 Twenty animals received siRNA-LNP beginning at 1, 2, 3, 4 or 5 days post-challenge.

231 VP35-targeting siRNA-LNP treatment resulted in up to 100% survival, even when

232 Six LNPs with sizes in the rang of 60-140 nm were evaluated

233 Additionally, we performed a small LNP formulation screen to iteratively optimize transgene

234 hedral shape for eLNPs compared to spherical LNPs, while x-ray scattering shows little disparity in i

235 formationally constrained lipids form stable LNPs, herein named constrained lipid nanoparticles (cLNP

236 don-optimized firefly luciferase into stable LNPs.

237 f-target liver uptake compared with standard LNP formulations.

238 Submicron LNPs (d(43) ~ 570-780 nm) were stabilized with Tween 80

239 We hypothesized that such LNP individuals could also tolerate two cups of milk per

240 a selective binding of the targeted-LNPs (T-LNPs) to Ly6C + inflammatory leukocytes.

241 with siRNAs against cyclin D1, CD38-targeted LNPs induced gene silencing in MCL cells and prolonged s

242 endent kinase inhibitor, into PD-L1-targeted LNPs led to a robust depletion of TAMCs and an attenuati

243 y, the delivery efficiency of PD-L1-targeted LNPs was robustly enhanced in the context of radiation t

244 nstrated a selective binding of the targeted-LNPs (T-LNPs) to Ly6C + inflammatory leukocytes.

245 ontrol of SUDV replication by VP35-targeting LNP confirm its therapeutic potential in combatting this

246 This work provides a proof-of-concept that LNP formulation of DNA vaccines can be used to produce m

247 We conclude that LNP subjects tolerate two cups of milk per day without a

248 These results demonstrate that LNP composition alone can be used to modulate the site o

249 In the present study, we demonstrate that LNP-Tmprss6 siRNA treatment of Hfe(-/-) and Hbb(th3/+) m

250 s to gene ontology annotations and find that LNP is more sensitive than the three previous methods.

251 n together, these observations indicate that LNP acts at a novel position in the early stages of symb

252 We propose that LNP functions at the earliest stage of the common nodula

253 The present results suggest that LNP drug products are highly complex and diverse in natu

254 fungus Glomus intraradices, suggesting that LNP plays a role in the common signaling pathway shared

255 Our results demonstrate that LNPs are appropriate carriers for mRNA in vivo and have

256 anoparticles (LNPs), it is hypothesized that LNPs devoid of targeting ligands can deliver RNA to T ce

257 pigs, and in Rhesus macaques, revealed that LNPs induced high titers of Dengue virus neutralizing an

258 tokine and chemokine profiling revealed that LNPs induced strong chemokine responses without signific

259 These data suggest that LNPs formulated with modified cholesterols can deliver g

260 The LNP method is based on a log-normal prior on the distrib

261 icating that this response was driven by the LNP components.

262 ion of poly(ethylene glycol) lipids from the LNP surface, 2) binding of distinct proteins to the nano

263 ctor did induce root hair deformation in the LNP antisense lines.

264 id (OA), an unsaturated fatty acid, into the LNP formulation significantly enhanced the delivery effi

265 Notably, the LNP targets liver microenvironmental cells fivefold more

266 ped to convolve the mass distribution of the LNP core with a function that describes the packaging di

267 portance of "helper lipid" components of the LNP formulation on the cellular uptake and transfection

268 tramuscular and intradermal injection of the LNP-encapsulated mRNA translated locally at the site of

269 hting the crucial role for the charge of the LNP.

270 of the nanoparticle dramatically reduced the LNP's ability to boost DEN-80E specific immune responses

271 merging from recent observations is that the LNP carrier acts as a powerful adjuvant for this novel v

272 used this new observation to infer that the LNP proportions of more than 30% seen in modern clinical

273 re of the oxidized cholesterols added to the LNP is systematically varied to show that the position o

274 ed in the serum of rabbits injected with the LNP-formulated DNA.

275 nt in a liquid crystalline nature within the LNP core.

276 For the LNPs used in this work, the evaluation of multiple param

277 Therefore, LNP uptake, endosomal escape, and mRNA translation with

278 Both the existence of these LNP cells and their aberrant signaling profiles provide

279 However, these LNPs are typically characterized and screened in an in v

280 Importantly, this LNP induces more than 85% of total protein production in

281 ls at clinical doses; unlike most LNPs, this LNP does not preferentially target hepatocytes.

282 Without this LNP-mediated stabilization, in Arabidopsis lnp1-1 lnp2-1

283 rs, and treatment of roots with antiserum to LNP inhibits their ability to undergo root hair deformat

284 A cluster approach to LNP design may facilitate the optimization of LNPs for o

285 tracellular diffusivity of eLNPs relative to LNPs, suggesting eLNP traffic to productive pathways for

286 ding insight into the tumor cell response to LNPs in vivo.

287 an year since 2007) are higher than the true LNP proportion.

288 scenarios reproduced this effect if the true LNP proportions were 20% or 25%, but not if the true LNP

289 ortions were 20% or 25%, but not if the true LNP proportions were 30% or greater.

290 ation might occur, we simulated varying true LNP proportions and true overall survival, and compared

291 reactive oxygen species (ROS)-responsive TS LNPs was designed and developed to encapsulate interleuk

292 not only serve as a method for understanding LNP product property, permitting control on product qual

293 Anti-VCAM/LNP selectively accumulated in the inflamed brain, provi

294 Anti-VCAM/LNP-mRNA mediated expression of thrombomodulin (a natura

295 Symptoms were recorded when LNP subjects ingested 240 mL regular or lactose-hydrolyz

296 10(-30) on 1/1000 uncorrelated pairs, while LNP reports significance correctly.

297 dditionally, in tumor cells transfected with LNP(IT), we observe upregulated pathways related to RNA

298 apoptosis in vitro following treatment with LNP-formulated dsP21-322-2'F (LNP-dsP21-322-2'F) or one

299 o three-fold higher than those observed with LNPs.

300 the mobility and chemical environment within LNPs at a molecular level.